Ambani Orgochem
Ambani Orgochem Q1 FY27 investor presentation: Revenue & Margins
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Ambani Orgochem's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
The presentation does not report specific quarterly revenue, sales, or volume figures. Reported Figures for the Quarter (Q1 FY27): - EBITDA: ₹457.4 lakhs (up 36% YoY) - Operating Margin: 16.2% (up 90 bps YoY) - Profit After Tax (PAT): ₹185.9 lakhs (up 21% YoY) - Year-on-Year
From Ambani Orgochem's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- The presentation does not report specific quarterly revenue, sales, or volume figures.
- Financial highlights show Total Income in ₹ Lakhs:
- FY24: 13,667.81
- FY25 (estimated): 19,392.76
- FY26 (estimated): 24,365.03
- EBITDA and Net Profit figures are provided for FY24 to FY26 but no direct quarter data.
- FY25 reported a loss of ₹85.47 lakhs mainly due to deferred tax, but underlying Profit Before Tax was ₹43.16 lakhs.
- Outlook on revenue indicates strong growth:
- Total income expected to grow from ₹13,667.81 lakhs in FY24 to ₹24,365.03 lakhs in FY26.
- Volume expansion is noted for key products:
- Salicylic Acid capacity expansion from ~50 T/month to ~200 T/month.
2 more points from Ambani Orgochem's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Ambani Orgochem said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Expansion of Eco-Friendly Acrylic Coatings & Adhesives capacity from ~2,000 T/month to ~4,500 T/month at Tarapur MIDC; capacity expected to increase by ~2.25×; manufacturing expansion underway (Page 10).
- Planned Salicylic Acid capacity expansion from ~50 T/month to ~200 T/month; supports downstream value-added products; selected downstream molecules progressing toward plant trials (Page 8).
- Peroxide derivatives: New molecule developments (5 additional peroxides) and backward integration via in-house development of 2 critical raw materials; pilot trials nearing completion (Page 7).
- Manufacturing expansion at Dahej, Gujarat, and other strategic locations to meet growing demand mentioned in vision roadmap (Page 15); environmental clearance and GPCB consent secured for Dahej facility (Page 17).
2 more points from Ambani Orgochem's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Ambani Orgochem said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Ambani Orgochem's call on order book
Pro opens every point from 15K+ earnings calls
Continue your research
What Ambani Orgochem's management said in earlier quarters
Arthneeti Pro · Annual
Ambani Orgochem and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ambani Orgochem Q1 FY27 results?
The presentation does not report specific quarterly revenue, sales, or volume figures. Reported Figures for the Quarter (Q1 FY27): - EBITDA: ₹457.4 lakhs (up 36% YoY) - Operating Margin: 16.2% (up 90 bps YoY) - Profit After Tax (PAT): ₹185.9 lakhs (up 21% YoY) - Year-on-Year
What is Ambani Orgochem share price analysis?
Ambani Orgochem currently shows a neutral. The stock trades at a P/E of 102.7 with a market cap of ₹140 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ambani Orgochem planning capital expenditure?
Expansion of Eco-Friendly Acrylic Coatings & Adhesives capacity from ~2,000 T/month to ~4,500 T/month at Tarapur MIDC; capacity expected to increase by ~2.25×; manufacturing expansion underway (Page 10).
Keep Ambani Orgochem on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.